Last reviewed · How we verify
ascending dose of GSK1292263 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ascending dose of GSK1292263 (ascending dose of GSK1292263) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ascending dose of GSK1292263 TARGET | ascending dose of GSK1292263 | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ascending dose of GSK1292263 CI watch — RSS
- ascending dose of GSK1292263 CI watch — Atom
- ascending dose of GSK1292263 CI watch — JSON
- ascending dose of GSK1292263 alone — RSS
Cite this brief
Drug Landscape (2026). ascending dose of GSK1292263 — Competitive Intelligence Brief. https://druglandscape.com/ci/ascending-dose-of-gsk1292263. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab